A Novel Human Antitumor Dimeric ImmunoRNase

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of immunotherapy

• Publication date

  2008-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/CJI.0b013e31816bc769PMID 18463541
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Explanation of the observation of pancreatic ribonuclease activity at pH 4.5.

  2009cited by this paper
• Targeting phosphodiesterases as a strategy for killing tumor cells

  2007cited by this paper
• Intracellular route and mechanism of action of ERB‐hRNase, a human anti‐ErbB2 anticancer immunoagent

  2007cited by this paper
• Interactions of the cytotoxic RNase A dimers with the cytosolic ribonuclease inhibitor

  2005cited by this paper
• A Fully Human Antitumor ImmunoRNase Selective for ErbB-2-Positive Carcinomas

  2004cited by this paper
• A new RNase‐based immunoconjugate selectively cytotoxic for ErbB2‐overexpressing cells

  2002cited by this paper
• A new human antitumor immunoreagent specific for ErbB2.

  2002cited by this paper
• Second generation antitumour human RNase: significance of its structural and functional features for the mechanism of antitumour action.

  2001cited by this paper
• The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials.

  2001cited by this paper
• Natural and engineered cytotoxic ribonucleases: therapeutic potential.

  1999cited by this paper
• A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity toward malignant cells.

  1999cited by this paper
• Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis.

  1998cited by this paper
• Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins.

  1998cited by this paper
• Ribonuclease A can be transformed into a dimeric ribonuclease with antitumor activity.

  1994cited by this paper
• Recombinant toxins for cancer treatment.

  1991cited by this paper
• Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.

  1989cited by this paper
• Activity staining of nucleolytic enzymes after sodium dodecyl sulfate-polyacrylamide gel electrophoresis: use of aqueous isopropanol to remove detergent from gels.

  1982cited by this paper

• New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab.

  2020cites this paper
• Biological Activities of Secretory RNases: Focus on Their Oligomerization to Design Antitumor Drugs

  2019cites this paper
• Superior Suppression of ErbB2-positive Tumor Cells by a Novel Human Triparatopic Tribody

  2017cites this paper
• Approaches to Endow Ribonucleases with Antitumor Activity: Lessons Learned from the Native Cytotoxic Ribonucleases

  2016cites this paper
• Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform

  2014cites this paper
• Design, Development, and Characterization of Recombinant Immunotoxins Targeting HER2/neu

  2013cites this paper
• 22. ImmunoRNase Fusions

  2013cites this paper
• Ribonucleases of different origins with a wide spectrum of medicinal applications.

  2011cites this paper
• Antibody-enzyme fusion proteins for cancer therapy.

  2011cites this paper
• Antibodies in single-chain format against tumour-associated antigens: present and future applications.

  2010cites this paper
• Ribonucleases and immunoRNases as anticancer drugs.

  2009cites this paper
• Human anti‐ErbB2 immunoagents – immunoRNases and compact antibodies

  2009cites this paper